Gilead Sciences... The Beat Goes On (GILD)

Health and Healthcare

Published: April 16, 2008 3:37 pm

Last Updated: March 26, 2020 12:16 pm

Gilead Sciences, Inc. (NASDAQ: GILD) posted results after the close today. Its Q1 revenues surged to $1.26 billion and non-GAAP earnings was $522.1 million, or $0.54 EPS. First Call had estimates at $0.48 EPS on $1.22 billion in revenues.

Gilead had cash and equivalents of $2.59 billion and generated $577.1 million of operating cash flows, which was offset by repurchases of $815.8 million of common stock. As of March 31, 2008, Gilead had approximately $2.15 billion remaining under this share repurchase program.

Its own product sales accounted for $1.14 Billion in Q1 revenues, up 36% because of a strong HIV franchise led by the continued strong uptake of Atripla.

Shares closed up 1.4% at $51.80 in normal trading, and shares rose 2.8% to $53.26 in after-hours trading. Its 52-week trading had been $35.22 to $53.20. Despite a 10-fold to 20-fold gain this decade, the company just keeps doing better and better.

Jon C. Ogg
April 16, 2008

Jon Ogg produces the Special Situation Investing Newsletter. He can be reached at [email protected] and he does not own securities in the companies he covers.

Travel Cards Are Getting Too Good To Ignore (sponsored)

Credit card companies are pulling out all the stops, with the issuers are offering insane travel rewards and perks.

We’re talking huge sign-up bonuses, points on every purchase, and benefits like lounge access, travel credits, and free hotel nights. For travelers, these rewards can add up to thousands of dollars in flights, upgrades, and luxury experiences every year.

It’s like getting paid to travel — and it’s available to qualified borrowers who know where to look.

We’ve rounded up some of the best travel credit cards on the market. Click here to see the list. Don’t miss these offers — they won’t be this good forever.